IP Library Granted Patent US 11,779,562
Granted Patent B2
US 11,779,562 · App. 17/865,024 · Granted Oct 10, 2023

Patent

Inventors: Harry Karelis (Perth, AU); Mara Gordon (Bodega Bay, CA); Stewart Smith (Bodega Bay, CA); Stewart Washer (Stirling, AU)
Assignee: Zelira Therapeutics Operations Pty Ltd
A61K31/352A61K31/05A61K47/06A61P25/20A61K36/185
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,779,562
App. No.
17/865,024
Granted
Oct 10, 2023
Kind
B2
Abstract

The present invention relates to a method for treating a sleep disorder. Preferably, the invention relates to a method for treating a sleep disorder comprising the step of administering a pharmaceutical composition comprising a Cannabis extract and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients or any combination thereof, the Cannabis extract comprising a terpene fraction comprising limonene in an amount of at least about 5.4% by weight of the terpene fraction.

Claims (29)

1. A pharmaceutical composition comprising a Cannabis extract and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients or any combination thereof, the Cannabis extract comprising:

Δ 9 -Tetrahydrocannabinol (THC) in an amount of from 50% to 90% by weight of the Cannabis extract;

Cannabidiol (CBD) in an amount of up to 10% by weight of the Cannabis extract;

Cannabinol (CBN) in an amount of up to 10% by weight of the Cannabis extract; and

a terpene fraction in an amount of more than 1% by weight of the Cannabis extract, the terpene fraction comprising:

a nerolidol being absent or in an amount of from about 0.01% to about 20% by weight of the terpene fraction;

beta-myrcene in an amount of up to 40% by weight of the terpene fraction;

linalool in an amount of at least 5% by weight of the terpene fraction;

alpha-pinene in an amount of from 0.001% to 20% by weight of the terpene fraction; and

beta-pinene in an amount of from 0.001% to 80% by weight of the terpene fraction.

2. The pharmaceutical composition of claim 1 , wherein the Cannabis extract comprises THC in an amount from 55 to 85% by weight of the extract.

3. The pharmaceutical composition of claim 1 , wherein the Cannabis extract comprises Δ 9 -Tetrahydrocannabivarin (THCV) in an amount from 0.001% to 10% by weight of the extract.

4. The pharmaceutical composition of claim 1 , wherein the terpene fraction comprises beta-pinene in an amount of at least 5% by weight of the terpene fraction.

5. The pharmaceutical composition of claim 1 , wherein the terpene fraction comprises alpha-pinene in an amount of from about 0.001% to 20% by weight of the terpene fraction.

6. The pharmaceutical composition of claim 5 , wherein the terpene fraction comprises alpha-pinene in an amount of at least 5% by weight of the terpene fraction.

7. The pharmaceutical composition of claim 1 , wherein the terpene fraction comprises a nerolidol in an amount of from about 0.01% to about 20% by weight of the terpene fraction.

8. The pharmaceutical composition of claim 1 , wherein the terpene fraction is present in an amount of up to 10% by weight of the Cannabis extract.

9. The pharmaceutical composition of claim 1 , wherein

the Cannabis extract comprises:

THC in an amount from 55 to 85% by weight of the extract;

CBD in an amount from 0.001% to 10% by weight of the extract;

CBN in an amount from 0.001% to 10% by weight of the extract;

THCV in an amount from 0.001% to 10% by weight of the extract;

the terpene fraction is present in an amount of up to 10% by weight of the Cannabis extract, and the terpene fraction comprises:

beta-pinene in an amount of at least 5% by weight of the terpene fraction;

alpha-pinene in an amount of from about 0.001% to 20% by weight of the terpene fraction;

beta-myrcene in an amount of up to about 40% by weight of the terpene fraction; and

a nerolidol in an amount of from about 0.01% to about 20% by weight of the terpene fraction.

10. The pharmaceutical composition of claim 1 , for treating a sleep disorder.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2023
From: KARELIS, HARRY; GORDON, MARA; SMITH, STEWART; WASHER, STEWART
To: ZELDA THERAPEUTICS OPERATIONS PTY LTD
Reel/Frame 063936/0373 →
CHANGE OF NAME Recorded Jun 13, 2023
From: ZELDA THERAPEUTICS OPERATIONS PTY LTD
To: ZELIRA THERAPEUTICS OPERATIONS PTY LTD
Reel/Frame 063936/0515 →
Continuity (3)
Continuation 16322447
Provisional Application 62370304 · Aug 3, 2016
Related Publication 20220347155A1 · Nov 3, 2022
Cited By (1)
US 12,239,628